Medical Pharmacology: Diabetes Management Practice Questions
Click on the correct answer.
Type I diabetes is associated with limited or absent
ß-cell function.
True
False
Insulinopenia may be associated with the following effects/effects:
Hypoglycemia
Hypertriglyceridemia
Ketoacidosis
A & B
B & C
A, B & C
Type I diabetes management:
Intensively insulin management with continuous glucose monitoring may be appropriate in many patients. (type I)
In adult patients, automated insulin delivery devices may be appropriate in adults possessing skills to use them. (type I).
Automated insulin delivery devices used in type I diabetes patients would likely decrease A1C levels and hypoglycemia.
A & B
B & C
A & C
A, B & C
Insulin administration in patients with type I diabetes:
50% of daily insulin dose is used to control glycemia between meal absorption.
50% of daily insulin dose is used to control glycemia after meals.
Both
Neither
Pramlintide:
This agent is based on the naturally occurring
ß-cell amylin.
Administration of pramlintide to type I diabetic patients on insulin may reduce
A1C and body weight.
Both
Neither
Non-insulin adjuncts which may be used in managing type I diabetes:
Metformin
Glucagon-like peptide 1 (GLP-1) receptor agonists, liraglutide or exenatide.
Both
Neither
Concerning successful pancreas and islet transplantation:
Normalization of glucose levels along with a decrease in type I diabetes-mediated microvascular complications may be expected.
Pancreas transplantation should be limited to patients with type I diabetes also undergoing concurrent renal transplantation or following renal transplantation or for patients with recurrent ketoacidosis along with severe hypoglycemia despite aggressive glycemic treatment.
Both
Neither
A number of agents have been used as adjuncts to insulin in treating type I diabetes; however, only pramlintide has been approved for treating type I diabetes.
True
False
Most individuals with type I diabetes should receive rapid-acting insulin analogs for the purpose of decreasing hypoglycemic risk.
True
False
Most patients with type I diabetes would benefit from multiple daily prandial and basal insulin injections or from continuous subcutaneous insulin delivery.
